OBJECTIVE: Despite concerns associated with the necessity of an additional fluorinated, high potency topical corticosteroid, the clotrimazole/betamethasone diproprionate combination remains a frequently prescribed topical agent in the U.S. This research was performed to better understand the circumstances in which physicians across specialties in the U.S. recommend the use of the combination medication in outpatient settings. Additionally, the study aimed to determine the diagnoses and characteristics of patients for whom the combination medication was prescribed. METHODS: Data from the National Ambulatory Medical Care Survey (1990 Survey ( -2000 were used to determine the demographic characteristics of patients with dermatologic diagnoses who were given a prescription for clotrimazole/betamethasone diproprionate. The most common diagnoses of patients treated with the drug were also determined. RESULTS: Family medicine physicians were more than twice as likely (OR: 2.61, 95% CI: 1.59, 4.30) and internists were more than 3 times as likely (OR: 3.52, 95% CI: 2.07, 5.97) to prescribe clotrimazole/betamethasone diproprionate compared to all other physicians when faced with a dermatologic diagnosis. Prescription rates of the combination medication were higher among patients of non-white race (OR: 1.55, CI: 1.07, 2.25). Contact dermatitis and other eczema ranked highest among diagnoses associated with the combination medication mention by family medicine physicians, internists, and pediatricians. CONCLUSIONS: The frequent use of clotrimazole/betamethasone diproprionate by primary care physicians is of concern. Use of alternative agents with anti-inflammatory and antifungal properties without the associated risks of high potency topical corticosteroids would be a preferable alternative.
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COST-EFFECTIVENESS OF BIMATOPROST VERSUS LATANOPROST PLUS ADJUNCTIVE PRODUCTS FOR GLAUCOMA TREATMENT
Walt JH 1 , Spalding JR 2 , Habib L 3 1 Allergan, Irvine, CA, USA; 2 University of Southern California, Los Angeles, CA, USA; 3 Keck Graduate Institute, Claremont, CA, USA OBJECTIVES: Prostamides have recently been introduced to treat glaucoma patients. We evaluated the effectiveness and pharmacoeconomic impact of these newer medications in treating patients with glaucoma. We compared effectiveness and costs of bimatoprost monotherapy versus latanoprost used with adjunctive therapies. METHODS: A pharmacoeconomic model was constructed based on a two-month naturalistic effectiveness trial comparing bimatoprost 0.03% (AWP of $53.13) in patients switched from all possible combination therapies with latanoprost 0.005% (AWP weighted total average
